We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

ERBA MANNHEIM

Erba Mannheim is an IVD solutions provider focused on improving health outcomes in developing nations. Originally fou... read more Featured Products: More products

Download Mobile App





Erba Introduces XL Range of Fully Automated Clinical Chemistry Systems at Medlab Middle East 2023

By LabMedica International staff writers
Posted on 08 Feb 2023

Erba Mannheim (London, UK) is introducing its latest XL range of fully automated clinical chemistry systems at the 22nd edition of Medlab Middle East Congress taking place live, in-person from 6-9 February 2023. More...

At Medlab Middle East 2023, Erba is showcasing the XL range of four fully automated clinical chemistry systems that incorporate state-of-the-art features. These rugged and performance-oriented systems boost lab productivity and throughput, making them an essential part of any start-up, medium or advanced lab. They support a wide test menu spanning routine clinical chemistry, electrolytes, immunoassays and coagulation tests. The XL range includes the XL 1000 fully automated clinical chemistry analyzer that guarantees high resolution measurement with automatic sample conveyor for comfortable workflow in laboratories with high sample throughput. It also includes the XL 200 fully automated random access clinical chemistry analyzer having a throughput of 200 tests/hr (photometric test) and 400 tests/hr with ISE (Na/K/Cl/Li). Also part of the XL range is the XL 640 fully automated biochemistry analyzer with a throughput of 640 tests per hour that is powerful and robust enough to keep up with the heavy demands of everyday testing, as well as the XL 180 that is designed to give convenience and flexibility in operation and good quality reporting for small and medium-sized laboratories.

From its hematology line, Erba is highlighting the H360 automated 3-part differential hematology analyzer that can be used as a complete blood count analyzer by small laboratories or as a second instrument. Within its coagulation line, Erba is showcasing the ECL 105 single channel semi-automated system for small laboratories that performs measurements of all clotting assays as well as DDimer. With a color touch-screen and intuitive user interface, the ECL-105 is simple to use and ensures quality results. Also featuring at the show is the LAURA Smart urine strip reader which is an efficient and compact solution for routine chemical urinalysis. The equipment's semi-automatic technology facilitates the sample process, contributing to the correct diagnosis of patients. In addition, Erba is presenting the EC90 electrolyte analyzer featuring clean biosensor and maintenance-free technology. Designed for easy use, efficient operation and reliability, the EC90 has an analysis time of only 35 seconds.

Related Links:
Erba Mannheim 


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Gold Member
Platelet Function Analyzer
AGGRENG-40
Gold Member
Platelet Function Analyzer
PL-12
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers combined a blood-based biomarker of Alzheimer’s disease with age, sex, and genetic risk to estimate future cognitive impairment risk in asymptomatic adults (Image Credit: Adobe Stock)

Blood Biomarker Model May Help Estimate Five- and 10-Year Cognitive Impairment Risk

Estimating future cognitive impairment risk remains challenging in cognitively healthy adults, particularly when biomarker findings are reduced to simple positive or negative results. Because mild cognitive... Read more

Molecular Diagnostics

view channel
Image Credit: Shutterstock

Lung Cancer Atlas Reveals Cellular Patterns Associated With Patient Prognosis

Lung cancer is a leading cause of cancer-related death worldwide and is characterized by substantial cellular heterogeneity. Even within a single tumor, cancer cells can vary in aggressiveness, while immune,... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Malaria is caused by Plasmodium parasites, primarily transmitted through the bites of infected female Anopheles mosquitoes (Image Credit: Adobe Stock)

Complete Malaria Genomes Could Improve Species Identification and Surveillance

Malaria remains a major global health challenge, with an estimated 282 million cases and 610,000 deaths worldwide in 2024. Although most research has focused on Plasmodium falciparum, Plasmodium ovale... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.